Production of SCO-101 is following the plan

Scandion Oncology had on February 28, 2019, a face-to-face meeting with our drug manufacturer Cambrex in Karlskoga, Sweden. It is a very pretty place and hometown for the Nobel family and their factories.

From Scandion the participants were Nils Brünner, CEO, and our three consultants within drug manufacturing, production and quality assurance René Egebro, Anders Clausen and Kaare Rasmussen. The meeting went very well and we feel confident that the production of SCO-101 is following the preset timelines with an expected delivery in June, 2019. SCO-101 will then be transported to our vendor being responsible for the final product manufacturing with an expected delivery time in Q4, 2019.

The plan is still to be ready to initiate the clinical phase II study in cancer patients in Q4, 2019.

I am very pleased with our collaboration with Cambrex that are allocating all the needed resources in order to deliver SCO-101 in June, 2019.

Nils Brünner

CEO

Here is  picture from the meeting at Cambrex: Cambrex meeting

Co-funded by the Horizon 2020 programme of the European Union
Co-funded by the COSME programme of the European Union